Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to Gilead's Third Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 5,017,913 | $420,701,826 | +1703% | 0.08% |
| 2. | Renaissance Technologies Jim Simons | 4,188,524 | $351,165,852 | -18% | 0.52% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,996,669 | $251,240,729 | -35% | 0.21% |
| 4. | Two Sigma Advisors John Overdeck And David Siegel | 2,487,800 | $208,577,152 | -61% | 0.48% |
| 5. | Point72 Asset Management Steve Cohen | 2,305,270 | $193,273,828 | +351% | 0.49% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | Director | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | Director | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | Director | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | Director | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | Director | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $91.28 | 5,000 | Officer | 73,127 | 2024-11-06 | Filing | |
| $91.50 | 5,000 | Officer | 99,599 | 2024-11-06 | Filing | |
| $91.50 | 20,590 | Officer | 104,599 | 2024-11-06 | Filing | |
| $83.83 | 2,000 | Officer | 100,189 | 2024-10-01 | Filing | |
| $84.50 | 21,246 | Officer | 102,189 | 2024-09-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 122,793,011 | $9,947,461,818 | 0.25% | |
| 2. | 111,822,428 | $9,058,734,893 | 0.19% | |
| 3. | 83,364,123 | $6,753,349,838 | 1.2% | |
| 4. | 59,657,126 | $4,832,824,186 | 1.18% | |
| 5. | 59,536,425 | $4,823,045,789 | 0.23% |
News See All
10 Best Pharma Stocks To Buy Right Now
Healthcare takes the concept of 'defensive' further than almost any industry, encompassing many companies that provide patient care, engage in the research and development of new treatments, and design...
Goldman Sachs' Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE
As the fourth quarter of 2024 settles in, the narrative surrounding stocks on Wall Street is starting to shift.
Goldman Sachs' List Of Stocks Popular With Mutual Fund Managers: Top 20 Stocks
As the fourth quarter of 2024 starts, the market is once again back to debating about the Federal Reserve's interest rate cuts.
Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and welcome to Gilead's Second Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today.
Should You Hold Gilead Sciences (GILD)?
Parnassus Investments, an investment management company, released the “Parnassus Value Equity Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Hedge Funds are Bullish on This Gene Therapy Stock
Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease.
9 Best Gene Therapy Stocks to Buy Now
In this article, we will be discussing the best gene therapy stocks to buy now. Before we move on to our list, let's take a look at the market outlook for gene therapies and understand the reasons behind...
23 Most Profitable Stocks of the Last 12 Months
In this article, we discuss the 23 most profitable stocks of the last 12 months.
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $-1.32, expectations were $-1.49. Gilead Sciences, Inc.
Billionaire Hedge Funds
